PSMA as a Target for Advanced Prostate Cancer: A Systematic Review

Objective Prostate-specific membrane antigen (PSMA) is a cell-surface protein widely expressed on most prostate cancer cells that has rapidly emerging clinical utility in the realm of cancer. This systematic review aims to evaluate efficacy as well cost-effectiveness PSMA roles diagnosis and treatment management. Background The use initial staging patients, early detection recurrence, response monitoring are critical improving treatment. We performed role Gallium-68 ( 68 Ga)-PSMA biochemical recurrence (BCR) Lutium-177 177 Lu)-PSMA theranostics. also investigated both ligands comparison current standard care. Methods In February 2022 we comprehensive existing literature. identified screened articles published from 1983 up January through PubMed. Only 1 study was included prior 2011. or therapy. Using Preferred Reporting Items for Systematic Reviews Meta-Analyses (PRSIMA) guidelines eligible were selected, relevant information extracted original articles. Results A total 26 analysis this review. These studies heterogeneous comprised five prospective including 336 three retrospective analyses 540 one phase III trial, survival analysis, randomized control reviews, meta-analyses, two in-vivo studies, four cost analyses. Conclusion diagnostic therapeutic appears more efficacious potentially less expensive than patients with BCR Current evidence suggests will fill an unmet need diagnostics ligand However, consensus not yet been reached further needed.